Knee Osteoarthritis Cell Therapy Cost-Effectiveness Model Parameters

A Markov model assesses the 40-year cost-effectiveness of mesenchymal stromal cell and extracellular vesicle treatments for knee osteoarthritis. Results include incremental cost-effectiveness ratios from hospital and societal perspectives, and projected surgical outcomes for 1,000 patients. The model and its baseline parameters were created by Iris W. A. Boot and published on figshare in March 2026.

Use Cases

• Compare incremental cost-effectiveness ratios (ICERs) for automated versus manual production methods of cell therapies.
• Estimate the reduction in total knee replacement surgeries per 1,000 patients when comparing cell treatment groups to standard of care.
• Perform sensitivity and scenario analyses using the model's baseline transition probabilities and cost parameters.
• Evaluate cost outcomes from both hospital and societal perspectives for Kellgren-Lawrence stage II knee osteoarthritis.

Strengths

• Model projects outcomes over a 40-year time horizon.
• Provides specific ICER values for four treatment scenarios versus standard of care.
• Includes secondary outcome metrics for surgical procedures per 1,000 patients.

Limitations

• The dataset is very small (13.5 KB), containing only model parameters and summary results, not patient-level data.
• Model outputs are inherently dependent on the study's assumptions and input parameters, which may not generalize.
• Geographic scope is limited to the Netherlands healthcare context.

Provenance

Source

figshare publication by Iris W. A. Boot.

Collection Method

Developed via a Markov model for health economic evaluation.

Time Range

Model projects a 40-year timeframe.

Freshness

Last updated March 2026.

Geography

Netherlands.